Fintel reports that Orbimed Advisors
has filed a 13D form
with the SEC disclosing ownership of
7.58MM
shares of Gracell Biotechnologies Inc. (GRCL).
This represents 11.2% of the company.
In their previous filing dated February 14, 2023
they reported 5.97MM shares and 8.80% of the company,
an increase in shares of 27.01%
and
an increase in total ownership of
2.40% (calculated as current – previous percent ownership).
Analyst Price Forecast Suggests 596.89% Upside
As of March 30, 2023,
the average one-year price target for Gracell Biotechnologies is $12.82.
The forecasts range from a low of $7.07 to a high of $21.00.
The average price target represents an increase of 596.89% from its latest reported closing price of $1.84.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Gracell Biotechnologies
is $0MM, a decrease of �%.
The projected annual non-GAAP EPS
is -$0.59.
What is the Fund Sentiment?
There are 52 funds or institutions reporting positions in Gracell Biotechnologies.
This is a decrease
of
1
owner(s) or 1.89% in the last quarter.
Average portfolio weight of all funds dedicated to GRCL is 0.11%,
an increase
of 29.14%.
Total shares owned by institutions decreased
in the last three months by 0.29% to 31,832K shares.
What are Large Shareholders Doing?
Temasek Holdings
holds 9,902K shares
representing 14.63% ownership of the company.
No change in the last quarter.
EcoR1 Capital
holds 3,343K shares
representing 4.94% ownership of the company.
In it’s prior filing, the firm reported owning 1,921K shares, representing
an increase
of 42.53%.
The firm
increased
its portfolio allocation in GRCL by 28.16% over the last quarter.
Capital International
holds 2,943K shares
representing 4.35% ownership of the company.
In it’s prior filing, the firm reported owning 3,016K shares, representing
a decrease
of 2.50%.
The firm
decreased
its portfolio allocation in GRCL by 32.66% over the last quarter.
Great Point Partners
holds 1,962K shares
representing 2.90% ownership of the company.
In it’s prior filing, the firm reported owning 449K shares, representing
an increase
of 77.12%.
The firm
increased
its portfolio allocation in GRCL by 154.09% over the last quarter.
EMRGX – EMERGING MARKETS GROWTH FUND INC Class M
holds 1,336K shares
representing 1.97% ownership of the company.
In it’s prior filing, the firm reported owning 1,368K shares, representing
a decrease
of 2.36%.
The firm
decreased
its portfolio allocation in GRCL by 36.27% over the last quarter.
Gracell Biotechnologies Background Information
(This description is provided by the company.)
Gracell Biotechnologies Inc. (
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
